Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on September 30, 2019. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The report addresses the formal termination of a material definitive agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a disclosure of a corporate event rather than a financial performance report.
Material Changes
- Termination of Agreement: On September 30, 2019, the Shared Facilities and Services Agreement between AgeX and Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) was terminated.
- Operational Relocation: AgeX had previously discontinued the shared use of Lineage's office and laboratory facilities in August 2019 upon moving operations to new facilities at 965 Atlantic Avenue, Alameda, California.
- Service Transition: While physical facilities were vacated in August, AgeX continued to utilize services provided by Lineage personnel until the agreement's formal termination in September.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various factors. Specific risks are referenced in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The filing does not provide new financial guidance or discuss specific contingencies beyond the termination of the shared services agreement.
Investor Verification Checklist
- Verify the financial impact of the termination of the Shared Facilities and Services Agreement on operating expenses.
- Confirm the status of the new facilities at 965 Atlantic Avenue and the completeness of the operational transition.
- Review the most recent Form 10-Q or 10-K for updated liquidity and cash runway metrics, as this 8-K does not contain them.
- Check for any remaining contractual obligations or liabilities with Lineage Cell Therapeutics, Inc. post-termination.